Abstract: Objective To observe the therapeutic effectiveness of Shenyankang in the treatment of adriamycin-induced nephropathy in rats, and to detect the expression of CTGF and FN in renal tissue of rats. Methods Rat models of nephropathy were established by injecting adriamycin into caudal vein. The rats were divided into blank control group, nephropathy model group, Shenyankang intervention group and prednisone group. Each group contained 10 SD rats aged 6-8 weeks. Urine protein level was detected 24 h after the last administration; arterial blood was taken for renal function; kidney was taken for pathological staining; the expression of CTGF and FN protein was detected by immunohistochemistry; the relative expression of CTGF and FN mRNA was detected by qPCR. Results (1) Shenyankang intervention treatment could significantly reduce urinary protein level in nephrotic rats (P<0.05). (2) Shenyankang could significantly reduce serum creatinine, urea and uric acid levels (P<0.05). (3) Shenyankang could significantly improve the renal pathological structure of nephrotic rats, and inhibit the level of renal fibrosis (P<0.05); (4) Shenyankang could significantly reduce glomerular sclerosis index in rats with nephropathy (P<0.05); (5) Immunohistochemical results showed that Shenyankang could significantly inhibit the expression of CTGF and FN proteins in renal tissues of nephrotic rats (P<0.05). (6) The results of qPCR showed that Shenyankang could significantly inhibit the expression of CTGF and FN mRNA in renal tissues of nephrotic rats (P<0.05). (7) For nephrotic rats, the overall improvement level of Shenyankang was weaker than that of prednisone, but the therapeutic effect was still obvious. Conclusions Shenyankang capsule has a definite therapeutic effect on adriamycin-induced nephropathy in rats. Shenyankang may play an anti-adriamycin nephropathy role by regulating CTGF and FN to inhibit renal fibrosis.